The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer

• Published in: Oncoimmunology Vol. 10; no. 1; p. 1938381
• Main Authors: Wei, Xiao-Li, Liu, Qian-Wen, Liu, Fu-Rong, Yuan, Sha-Sha, Li, Xiao-Fen, Li, Jia-Ning, Yang, An-Li, Ling, Yi-Hong
• Format: Journal Article
• Language: English
• Published: Taylor & Francis 01.01.2021; Taylor & Francis Group
• Subjects: biomarker; Epstein-Barr virus-associated gastric cancer; immunotherapy; Original Research; Programmed death ligand-1

The effect of anti-programmed cell death 1 (PD-1) antibody in Epstein-Barr virus-associated gastric cancer (EBVaGC) was debatable, and no predictive biomarkers for efficacy have been reported. Public reports on anti-PD-1 antibody monotherapy-treated EBVaGC with available programmed death ligand-1 (P...